One system. Multiple pathways. Any RNA.
Redefining how the world treats its most complex diseases with safe, scalable, multi-target RNA medicines.
Beyond single targets
The SymphoRNA advantage
Complex diseases involve many pathways — yet most medicines focus on just one. That’s why they fail. Our platform makes the multi-pathway approach feasible, safe, and scalable. We’ve proven that combinations work better than single targets, and now we’re building RNA medicines to achieve what traditional therapies never could —
powerful and affordable.
We built the delivery system others couldn’t. Proven up to 99% lung targeting. Safe at high therapeutic dose. More than 4,000× cheaper than LNPs and stable at room temperature for over 50 days.
Then we added the therapeutic engine: delivering multiple mRNAs, demonstrating siRNA + mRNA synergy.
Together, this makes us more than a platform. By uniting groundbreaking delivery with therapeutic versatility, we’re building RNA medicines that succeed where single-target drugs fail — starting with one of the world’s most urgent challenges:
Idiopathic Pulmonary Fibrosis.